Asensus Surgical Financial Statements (ASXC)
|
|
|
|
Report date
|
|
|
30.06.2022 |
31.12.2022 |
02.03.2023 |
21.03.2024 |
29.04.2024 |
|
13.08.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
|
7.09 |
7.09 |
8.58 |
8.58 |
|
14.2 |
|
Operating Income, bln rub |
|
|
|
-75.7 |
-75.7 |
-78.1 |
-78.1 |
|
-66.7 |
|
EBITDA, bln rub |
? |
|
|
-63.8 |
-64.3 |
-74.4 |
-74.4 |
|
-62.8 |
|
Net profit, bln rub |
? |
|
|
-75.6 |
-75.6 |
-78.4 |
-78.4 |
|
-82.7 |
|
|
OCF, bln rub |
? |
|
|
-58.9 |
-58.9 |
-63.6 |
-63.6 |
|
-55.0 |
|
CAPEX, bln rub |
? |
|
|
1.28 |
1.28 |
0.561 |
0.561 |
|
0.257 |
|
FCF, bln rub |
? |
|
|
-60.2 |
-60.2 |
-64.2 |
-64.2 |
|
-55.2 |
|
Dividend payout, bln rub
|
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
|
|
Dividend payout ratio, %
|
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
|
71.9 |
71.6 |
73.1 |
73.1 |
|
66.2 |
|
Cost of production, bln rub |
|
|
|
10.9 |
10.9 |
13.6 |
13.6 |
|
14.7 |
|
R&D, bln rub |
|
|
|
28.9 |
28.9 |
37.0 |
37.0 |
|
32.9 |
|
Interest expenses, bln rub |
|
|
|
0.410 |
0.410 |
0.000 |
0.000 |
|
0.499 |
|
|
Assets, bln rub |
|
|
147.4 |
116.1 |
116.1 |
60.5 |
60.5 |
|
38.5 |
|
Net Assets, bln rub |
? |
|
131.4 |
99.6 |
99.6 |
33.4 |
33.4 |
|
-11.3 |
|
Debt, bln rub |
|
|
5.19 |
5.54 |
5.54 |
5.68 |
5.68 |
|
20.4 |
|
Cash, bln rub |
|
|
94.2 |
70.5 |
70.5 |
21.1 |
21.1 |
|
7.78 |
|
Net debt, bln rub |
|
|
-89.0 |
-65.0 |
-65.0 |
-15.4 |
-15.4 |
|
12.7 |
|
|
Ordinary share price, rub |
|
|
0.400 |
0.347 |
0.347 |
0.319 |
0.319 |
|
|
|
Number of ordinary shares, mln |
|
|
|
236.5 |
236.5 |
249.7 |
249.7 |
|
272.3 |
|
|
Market cap, bln rub |
|
|
0 |
82 |
82 |
80 |
80 |
|
0 |
|
EV, bln rub |
? |
|
-89 |
17 |
17 |
64 |
64 |
|
13 |
|
Book value, bln rub |
|
|
131 |
100 |
98 |
32 |
32 |
|
-11 |
|
|
EPS, rub |
? |
|
|
-0.32 |
-0.32 |
-0.31 |
-0.31 |
|
-0.30 |
|
FCF/share, rub |
|
|
|
-0.25 |
-0.25 |
-0.26 |
-0.26 |
|
-0.20 |
|
BV/share, rub |
|
|
|
0.42 |
0.41 |
0.13 |
0.13 |
|
-0.04 |
|
|
EBITDA margin, % |
? |
|
|
-899.6% |
-907.1% |
-867.4% |
-867.4% |
|
-442.4% |
|
Net margin, % |
? |
|
|
-1 066% |
-1 066% |
-914.5% |
-914.5% |
|
-582.8% |
|
FCF yield, % |
? |
|
0.00% |
-73.4% |
-73.4% |
-80.6% |
-80.6% |
|
|
|
ROE, % |
? |
|
0.00% |
-75.8% |
-75.8% |
-234.7% |
-234.7% |
|
730.3% |
|
ROA, % |
? |
|
0.00% |
-65.1% |
-65.1% |
-129.6% |
-129.6% |
|
-214.8% |
|
|
P/E |
? |
|
|
-1.09 |
-1.09 |
-1.02 |
-1.02 |
|
0 |
|
P/FCF |
|
|
|
-1.36 |
-1.36 |
-1.24 |
-1.24 |
|
0 |
|
P/S |
? |
|
|
11.6 |
11.6 |
9.28 |
9.28 |
|
0 |
|
P/BV |
? |
|
0.00 |
0.82 |
0.84 |
2.47 |
2.47 |
|
0 |
|
EV/EBITDA |
? |
|
|
-0.27 |
-0.27 |
-0.86 |
-0.86 |
|
-0.20 |
|
Debt/EBITDA |
|
|
|
1.02 |
1.01 |
0.21 |
0.21 |
|
-0.20 |
|
|
R&D/CAPEX, % |
|
|
|
2 263% |
2 263% |
6 599% |
6 599% |
|
12 821% |
|
|
CAPEX/Revenue, % |
|
|
|
18.0% |
18.0% |
6.54% |
6.54% |
|
1.81% |
|
| Asensus Surgical shareholders |
